VSTM: 900 mg advances across indications, with three Phase III starts planned and a data-rich 2027 ahead

Verastem, Inc. (VSTM) is advancing its 900 mg dose of VS-7375 across multiple indications, focusing on selective target inhibition and chemo-free combinations. The company plans to initiate three Phase III trials and expects multiple clinical updates in 2027, with cash reserves lasting through the first half of 2028, according to its 8th Annual Wolfe Research Healthcare Conference.

Original reporting
Published Nov 10, 2026, 10:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 4:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
VSTM: 900 mg advances across indications, with three Phase III starts planned and a data-rich 2027 ahead — source image
Decision brief

The 30-second read

$VSTMBullishMed
01

Why it matters

The announcement adds concrete milestones to Verastem's pipeline, which may influence short‑term trading and longer‑term valuation.

02

Market read

New Phase III starts and a clear cash runway are material for biotech investors and could drive modest buying pressure.

03

What to watch

Potential competition in the same target space and regulatory timelines could moderate upside.

Relevance 7/10Novelty 7/10Timing: ahead of 2027 trial updates

Background

Verastem presented at its 8th Annual Wolfe Research Healthcare Conference, outlining its upcoming clinical development plan.

Company-level read

Ticker impact

$VSTMBullishHigh confidence
Context

Verastem announced a 900 mg dose advancing across indications with three Phase III trial starts planned and cash to fund through H1 2028.

Expected impact

likely upward pressure as the market prices in the expanded pipeline and cash runway

Evidence & confidence

Biotech investors typically reward new late‑stage trial initiations, especially with clear funding, which can lead to short‑term buying.

Market effects

strengthens the oncology/targeted‑therapy sector outlook

U.S. biotech market may see modest uplift

limited to investors tracking late‑stage biotech pipelines

Counterpoint

If trial initiation timelines slip or data disappoint, the stock could face pressure despite cash runway.

Key entities

  • Verastem, Inc.

    U.S. biotech focused on selective target inhibition.

Related articles

$VSTMMedAI 8/10

What Verastem (VSTM) Said on Its Q3 Earnings Call

Verastem (VSTM) reported Q3 earnings, highlighting clinical trial data for VS-7375 in pancreatic, colorectal, and lung cancers. The company saw positive responses in early-stage trials and plans to initiate phase III trials. Verastem raised $250M in an October offering, ending Q3 with $422.8M in cash. The company expects to complete enrollment in some trials by year-end and in others by mid-2027.

$VSTMMedAI 8/10

Verastem (VSTM) Q3 2026 Earnings Call Transcript

Verastem (VSTM) reported Q3 2026 earnings, highlighting FDA acceptance of its new blister pack NDA with a February 2027 PDUFA date. The company shared positive clinical data for VS-7375 in pancreatic, colorectal, and lung cancers, raising $250M to fund operations into 2028. Q3 revenue for AVMAPKI FAKZYNJA CO-PACK was $24M, with plans to expand its use in approved indications. CEO Dan Patterson will step down at the end of 2026, succeeded by Michael Bailey.

$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.